Skip to content
Rivals’ interest in the $7 billion market shows the drug industry’s renewed focus on vaccines
Source link
Tags: Annaliesa Anderson, Art Hirt, Azra Behlim, BioNTech SE, BNTX, C&E Industry News Filter, clothing, Clothing/Textiles, Consumer Goods, Content Types, corporate, Corporate/Industrial News, Daina Graybosch, dealing, Earnings, Factiva Filters, Financial Investment Services, Financial Performance, Financial Services, general news, GSK, GSK.LN, Health, healthcare, Healthcare/Life Sciences, Immunizations, industrial news, Industry Profiles, investing, Investing/Securities, life sciences, Louise Chen, Market Share, Marketing, Markets, Markets/Marketing, Medical Conditions, medical treatments, Medical Treatments/Procedures, medications, Merck, Moderna, MRK, MRNA, PCVX, PFE, Pfizer, Pharmaceuticals, Phil Dormitzer, political, Political/General News, procedures, Respiratory Tract Diseases, Retail, Retail/Wholesale, Ryan Mire, Sales Figures, securities, security brokering, Security Brokering/Dealing, specialized drugs, Specialized Drugs/Medications, SYND, Textiles, UK:GSK, Vaccines, Vaxcyte, wholesale, Wholesalers, WSJ-PRO-WSJ.com, wsjhealth
